image: Cover image. view more
Credit: Future Science Group
The Future Science Group (FSG) published journal, Melanoma Management, has released a special issue highlighting the advancements made in viral immunotherapies and vaccines in the melanoma field.
Over the last few years, melanoma has been at the center of some of the latest advances in cancer immunotherapy, with monoclonal antibodies such as anti-CTLA-4 and anti-PD-1 currently FDA- approved for use in late stage disease. Moreover, focus is now being given to potential melanoma vaccines, comprised of tumor-associated antigens and intralesional viral therapies.
Highlights from the special issue include articles discussing how dendritic cell vaccines have developed since their inception to their use today in various clinical trials, as well as a comment on ongoing clinical trials for a variety of cancer vaccines. The issue further appraises various vaccine targets and intralesional therapies currently being developed for melanoma, as well as those already used in the clinic today, such as the oncolytic immunotherapy talimogene laherparepvec (T-VEC).
Guest Editor for the special issue, Robert O Dillman (AiVita Biomedical, CA, USA) stated: "This special focus issue of Melanoma Management highlights the latest advancements in melanoma immunotherapy with respect to cancer vaccines and viral-based therapies, with a range of articles discussing the developments in various vaccine candidates for melanoma as well as expert opinions and experiences with such vaccines both in clinical trials and in standard practice."
"The use of immunotherapies in melanoma has provided the field with exciting results and opened further avenues for treating the malignancy," commented commissioning editor for Melanoma Management Sebastian Dennis-Beron. "It has been a pleasure to work with a group of renowned experts on the fore-front of this field to develop this special issue on these immunotherapies, which could revolutionize melanoma treatment in the future".
View the special focus issue: http://www.futuremedicine.com/toc/mmt/3/4
Dillman's foreword as guest editor is free to read, here: http://www.futuremedicine.com/doi/full/10.2217/mmt-2016-0030
###
About Melanoma Management
Melanoma Management launched in 2014 and is currently a quarterly forum for reviews, opinion, analysis and original research from international experts. The aim of our journal is to provide concise, up-to-date and clinically relevant content for the melanoma community through publication in both print and online formats and through our new partnership with Oncology Central (http://www.oncology-central.com).
About Future Science Group
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological and scientific research. FSG's portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine. The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards. http://www.futuresciencegroup.com
Journal
Melanoma Management